Peijia Medical (9996) has announced unaudited operating statistics for the year ended December 31, 2025. Revenue reached approximately RMB700 million to RMB720 million, up from RMB615.5 million in the previous year, reflecting a year-on-year increase of about 13.7% to 17%, attributed primarily to strong performance in all three neurointerventional product lines and continued market share expansion in the transcatheter aortic valve replacement (TAVR) segment.

Neurointerventional revenue growth was supported by rising demand for core products across vascular access, hemorrhagic, and ischemic product lines. Among these drivers were increased market acceptance of DCwire Micro Guidewire, the launch of the YonFlow Flow Diverting Stent, and higher sales volumes of the Syphonet Stent Retriever and Tethy AS Aspiration Catheter. Despite price reductions in balloon dilatation catheters under volume-based procurement, overall balloon revenue remained stable on the back of expanded sales volumes, notably for the Fastunnel Delivery Balloon Dilatation Catheter.

In TAVR, the commercialized portfolio, including TaurusOne, TaurusElite, and TaurusMax systems, extended coverage to around 130 more hospitals, reaching over 780 sites overall by the end of 2025. Approximately 3,900 TAVR units were implanted during this period, registering a 14.4% year-on-year increase. With regulatory approval for the TaurusTrio Transcatheter Aortic Valve System secured in December 2025, expanded commercialization in the aortic regurgitation market is anticipated.

Management noted that these figures remain preliminary and unaudited, pending the full annual results announcement expected in March 2026.